CIK Cells Treatment of Gynecologic Tumor

Objective To observe cytokine-induced killer cells(CIK cells)cytotoxic activity in vitro,and to observe the short-term clinical efficacy,immunological activity and side effects of CIK cells in treating gynecologic tumor.Methods A total of 22 patients with gynecological malignancies were recorded with CIK cell therapy from July 2007 to March 2010,in which 11 cases were ovarian cancer,11 cases were uterine cancer.Peripheral blood mononuclear cells(PBMC)from patients with standard treatment protocols were induced to CIK cells in vitro,then phenotype of CIK cells were observed and cytotoxicity in vitro was measured by MTT method.All patients received a certain dose of CIK cells in adoptive immunotherapy and the recent clinical efficacy,immune response and adverse effects were observed.Results Cytotoxic activity of CIK cells in vitro anti-ratio was(82.33 ± 9.35)% and(61.59 ± 13.59)% respectively when the ratio of effector cell to target cell was 16:1and 8:1.In the recent clinical efficacy evaluation,4 of 11 cases of ovarian cancer were partial remission and recent effective ratio was 66.67%,the disease control rate was 66.67%.6 of 11 uterine cancer cases were partial remission and recent effective ratio was 100%.No tumor progressing period was 4 to 26 months and the median was 13 months.The cells surface markers CD3+,CD4+,CD8+ of patient's PBMC had increased(P0.05) compared with that before transfusion,which meant patient's specific immune response was induced by CIK cells.No adverse reaction was observed during the infusion of CIK cells for the 22 patients.Conclusion CIK cells have good clinical efficacy for gynecological tumor.